Alan M. Garber
Academic Appointments
- Emeritus Faculty, Acad Council, Medicine - Primary Care Outcomes Research
- Member, Stanford Cancer Institute
- Member, Bio-X
Key Documents
Contact Information
- Academic Offices
Personal Information Email Tel (617) 496-5100Administrative contact Marie Dach Email Tel Work 617-496-5100
Professional Overview
Administrative Appointments
- Chair, Medicare Coverage Advisory Committee, Centers for Medicare and Medicaid Services (2005 - 2007)
- Director, Health Care Program, National Bureau of Economic Research, Inc. (1990 - 2009)
- Director, Center for Health Policy, Institute for International Studies, Stanford University (1997 - 2011)
- Director, Center for Primary Care and Outcomes Research, Stanford University School of Medicine (1997 - 2011)
Honors and Awards
- Research Associate, National Bureau of Economic Research, Inc. (1986)
- Fellow, Royal College of Physicians (2010)
- Member, Institute of Medicine (1998)
- Member, Association of American Physicians (2003)
- Member, American Society for Clinical Investigation (1998)
- Fellow, Association for Health Services Research (AcademyHealth) (1996)
Professional Education
| A.B.: | Harvard College, Economics (1976) |
| Ph.D.: | Harvard University, Economics (1982) |
| M.D.: | Stanford University (1983) |
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
Topics in the health economics of aging; health, insurance; optimal screening intervals; cost-effectiveness of, coronary surgery in the elderly; health care financing and delivery, in the United States and Japan; coronary heart disease
Publications
- Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol. 2013; (12): 1250-8
- An economic analysis of conservative management versus active treatment for men with localized prostate cancer. J Natl Cancer Inst Monogr. 2012; (45): 250-7
- Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis. Ann Surg. 2012; (1): 117-24
- Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2011; (5): 489-96
- Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011; (1): 1-11
- How CER could pay for itself--insights from vertebral fracture treatments. N Engl J Med. 2011; (15): 1390-3
Help
Trial Administration